HIPRABOVIS SOMNI/LktEmulsion for injection for cattle

Land: Irland

Sprog: engelsk

Kilde: HPRA (Health Products Regulatory Authority)

Aktiv bestanddel:

Mannheimia haemolytica biotype a, serotype a1 leukotoxoid; Haemophilus somnus bailie strain, inactivated

Tilgængelig fra:

Laboratorios Hipra S.A.

ATC-kode:

QI02AB

INN (International Name):

Mannheimia haemolytica biotype a, serotype a1 leukotoxoid; Haemophilus somnus bailie strain, inactivated

Dosering:

.

Lægemiddelform:

Emulsion for injection

Recept type:

POM: Prescription Only Medicine as defined in relevant national legislation

Terapeutisk gruppe:

Cattle

Terapeutisk område:

Inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia)

Terapeutiske indikationer:

Immunological - Inactivated Vaccine

Autorisation status:

Authorised

Autorisation dato:

2005-10-27

Produktets egenskaber

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
HIPRABOVIS SOMNI/Lkt
Emulsion for injection for cattle.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Emulsion for injection.
Ivory-coloured homogeneous emulsion.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle from 2 months of age.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
To reduce the clinical signs and lung lesions caused by_ Mannheimia
haemolytica_ serotype A1 and_ Histophilus somni_
in calves from 2 months of age.
ONSET OF IMMUNITY:
3 weeks.
DURATION OF PROTECTION:
Not demonstrated.
4.3 CONTRAINDICATIONS
Do not vaccinate unhealthy animals.
Do not use in case of hypersensitivity to the active substances, to
the adjuvant or to any of the excipients.
ACTIVE SUBSTANCES:
_Mannheimia haemolytica_ Biotype A serotype A1,
inactivated cell free suspension containing leukoxid Ph. Eur.
-
ELISA > 2.8 (*)/dose
Inactivated_ Histophilus somni_ Bailie strain
-
MAT > 3.3 (**)/dose
(*) A minimum of 80% of vaccinated rabbits show ELISA value of > 2.0;
the mean ELISA is > 2.8
(**) A minimum of 80% of vaccinated rabbits show a log
2
MAT value of
3.0;
the mean log
2
MAT > 3.3
ADJUVANT:
Liquid paraffin
18.2 mg/dose
EXCIPIENTS:
Thiomersal
0.2 mg/dose
For a full list of excipients, see section 6.1.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_1_
_8_
_/_
_1_
_2_
_/_
_2_
_0_
_1_
_4_
_C_
_R_
_N_
_ _
_7_
_0_
_1_
_7_
_6_
_2_
_8_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.4 SPECI